Skip to main content

Table 1 Baseline characteristics of safety and per protocol patients per up-dosing regimen

From: Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients

  Safety population Per protocol
  Regular Intermediate Fast Overall Regular Intermediate Fast Overall
Patients (n) 6 21 21 48 5 19 15 39
Mean age ± SD (yrs) 27.5 ± 4.9 32.1 ± 11.4 31.2 ± 10.6 31.2 ± 10.4 27.2 ± 5.5 31.8 ± 11.3 33.1 ± 10.4 31.7 ± 10.3
BMI ± SD (kg/m2) 27.5 ± 5.9 24.4 ± 3.5 26.7 ± 6.2 25.8 ± 5.2 27.7 ± 6.6 24.5 ± 3.4 26.7 ± 5.9 25.8 ± 4.9
Patients with other allergies n (%) 5 (83.3%) 12 (57.1%) 12 (57.1%) 29 (60.4%) 4 (80%) 10 (52.6%) 9 (60.0%) 23 (59.0%)
SPT HDM D. pter ± SD (mm) 6.5 ± 3.1 6.6 ± 2.7 7.4 ± 4.5 6.9 ± 3.6 7.0 ± 3.2 6.6 ± 2.8 8.0 ± 5.2 7.2 ± 3.9
SPT HDM D. far ± SD (mm) 7.8 ± 2.6 7.1 ± 1.9 7.0 ± 3.9 7.1 ± 3.0 8.2 ± 2.8 7.0 ± 1.9 7.2 ± 4.4 7.2 ± 3.2
ssIgE ± SD (U/ml) 16.0 ± 19.7 23.4 ± 23.8 26.2 ± 28.2 23.7 ± 25.1 17.1 ± 21.8 24.5 ± 24.7 34.1 ± 29.9 27.3 ± 26.5